WO2003046009A1 - Anticorps de neutralisation du recepteur alpha 1 de l'il13 - Google Patents
Anticorps de neutralisation du recepteur alpha 1 de l'il13 Download PDFInfo
- Publication number
- WO2003046009A1 WO2003046009A1 PCT/JP2002/012393 JP0212393W WO03046009A1 WO 2003046009 A1 WO2003046009 A1 WO 2003046009A1 JP 0212393 W JP0212393 W JP 0212393W WO 03046009 A1 WO03046009 A1 WO 03046009A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor
- neutralizing antibody
- inhibiting
- cell response
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002468950A CA2468950A1 (fr) | 2001-11-27 | 2002-11-27 | Anticorps de neutralisation du recepteur alpha 1 de l'il13 |
US10/496,869 US20050154192A1 (en) | 2001-11-27 | 2002-11-27 | Anti-il13 receptor alpha1 neutralizing antibody |
EP02795425A EP1449851A4 (fr) | 2001-11-27 | 2002-11-27 | Anticorps de neutralisation du recepteur alpha 1 de l'il13 |
JP2003547458A JPWO2003046009A1 (ja) | 2001-11-27 | 2002-11-27 | 抗IL13レセプターα1中和抗体 |
AU2002361122A AU2002361122A1 (en) | 2001-11-27 | 2002-11-27 | ANTI-IL13 RECEPTOR Alpha1 NEUTRALIZING ANTIBODY |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-361795 | 2001-11-27 | ||
JP2001361795 | 2001-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003046009A1 true WO2003046009A1 (fr) | 2003-06-05 |
Family
ID=19172396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/012393 WO2003046009A1 (fr) | 2001-11-27 | 2002-11-27 | Anticorps de neutralisation du recepteur alpha 1 de l'il13 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050154192A1 (fr) |
EP (1) | EP1449851A4 (fr) |
JP (1) | JPWO2003046009A1 (fr) |
AU (1) | AU2002361122A1 (fr) |
CA (1) | CA2468950A1 (fr) |
WO (1) | WO2003046009A1 (fr) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006504623A (ja) * | 2002-03-22 | 2006-02-09 | アムラッド オペレイションズ ピーティーワイ リミティッド | インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体 |
JP2008508881A (ja) * | 2004-08-04 | 2008-03-27 | アムジェン インコーポレイテッド | Dkk−1に対する抗体 |
JP2008526187A (ja) * | 2005-01-03 | 2008-07-24 | エフ.ホフマン−ラ ロシュ アーゲー | IL−13受容体α1に対する抗体とその使用 |
JP2008528995A (ja) * | 2005-01-27 | 2008-07-31 | ザ バインディング サイト リミテッド | 悪性プラズマ細胞疾患の検出又はモニタリング方法 |
JP2010507364A (ja) * | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | インターロイキン−13レセプターアルファ1の高親和性抗体アンタゴニスト |
US8207304B2 (en) | 2006-10-19 | 2012-06-26 | Csl Limited | Antibody antagonists of interleukin-13 receptor α1 |
EP2530090A2 (fr) | 2006-10-19 | 2012-12-05 | CSL Limited | Anticorps anti-IL-13R alpha 1 et leurs utilisations |
WO2020197502A1 (fr) | 2019-03-26 | 2020-10-01 | Aslan Pharmaceuticals Pte Ltd | Traitement faisant intervenir un anticorps anti-il-13r ou un fragment de liaison de celui-ci |
WO2022186773A1 (fr) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DE LA DERMATITE ATOPIQUE À L'AIDE D'UN ANTICORPS ANTI-IL-13Rα1 OU D'UN FRAGMENT DE LIAISON ASSOCIÉ CHEZ UNE POPULATION ALLERGIQUE |
WO2022186772A1 (fr) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DE LA DERMATITE ATOPIQUE À L'AIDE D'UN ANTICORPS ANTI-IL-13Rα1 OU D'UN FRAGMENT DE LIAISON ASSOCIÉ |
WO2023048651A1 (fr) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Procédé de traitement de la dermatite atoptique modérée à grave |
WO2023048650A1 (fr) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DU PRURIT FAISANT INTERVENIR UN ANTICORPS ANTI-IL13Rα1 OU UN FRAGMENT DE LIAISON DE CELUI-CI |
WO2023075702A1 (fr) | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Formulation d'anticorps anti-il-13r |
WO2024043837A1 (fr) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | Formulation d'anticorps anti-il13r à haute concentration |
WO2024054157A1 (fr) | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Traitement de la perte de sommeil ou des troubles du sommeil chez des patients atteints de dermatite |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
BRPI0810561A2 (pt) * | 2007-04-23 | 2019-09-24 | Wyeth Corp | métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13. |
JP5903382B2 (ja) | 2009-08-29 | 2016-04-13 | アッヴィ・インコーポレイテッド | 治療用dll4結合タンパク質 |
RU2646139C1 (ru) * | 2009-09-03 | 2018-03-01 | Мерк Шарп И Доум Корп. | Анти-gitr-антитела |
EP2542582A4 (fr) | 2010-03-02 | 2013-12-04 | Abbvie Inc | Protéines thérapeutiques de liaison à dll4 |
US9631024B2 (en) | 2014-06-23 | 2017-04-25 | Bionomics, Inc. | Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors |
US20200158716A1 (en) * | 2017-07-17 | 2020-05-21 | Massachusetts Institute Of Technology | Cell atlas of healthy and diseased barrier tissues |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2000044407A2 (fr) * | 1999-02-01 | 2000-08-03 | Amgen Canada | Materiaux et methodes d'inhibition de l'accroissement cellulaire d'hodgkin et de reed sternberg |
-
2002
- 2002-11-27 EP EP02795425A patent/EP1449851A4/fr not_active Withdrawn
- 2002-11-27 JP JP2003547458A patent/JPWO2003046009A1/ja not_active Withdrawn
- 2002-11-27 AU AU2002361122A patent/AU2002361122A1/en not_active Abandoned
- 2002-11-27 CA CA002468950A patent/CA2468950A1/fr not_active Abandoned
- 2002-11-27 WO PCT/JP2002/012393 patent/WO2003046009A1/fr not_active Application Discontinuation
- 2002-11-27 US US10/496,869 patent/US20050154192A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
AKAIWA M. ET AL.: "Localization of human interleukin 13 receptor in non-haematopoietic cells", CYTOKINE, vol. 13, no. 2, January 2001 (2001-01-01), pages 75 - 84, XP002961741 * |
GRABER P. ET AL.: "The distribution of IL-13 receptor alpha1 expression on B cells, T cells and monocytes and its regulation by IL-13 and IL-4", EUR. J. IMMUNOL., vol. 28, no. 12, 1998, pages 4286 - 4298, XP002961740 * |
See also references of EP1449851A4 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8221755B2 (en) | 2002-03-22 | 2012-07-17 | Zenyth Operations Pty Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ralpha1) |
JP2010031015A (ja) * | 2002-03-22 | 2010-02-12 | Zenyth Operations Pty Ltd | インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体 |
JP2006504623A (ja) * | 2002-03-22 | 2006-02-09 | アムラッド オペレイションズ ピーティーワイ リミティッド | インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体 |
JP2008508881A (ja) * | 2004-08-04 | 2008-03-27 | アムジェン インコーポレイテッド | Dkk−1に対する抗体 |
JP4840939B2 (ja) * | 2004-08-04 | 2011-12-21 | アムジェン インコーポレイテッド | Dkk−1に対する抗体 |
JP2008526187A (ja) * | 2005-01-03 | 2008-07-24 | エフ.ホフマン−ラ ロシュ アーゲー | IL−13受容体α1に対する抗体とその使用 |
JP2008528995A (ja) * | 2005-01-27 | 2008-07-31 | ザ バインディング サイト リミテッド | 悪性プラズマ細胞疾患の検出又はモニタリング方法 |
JP2013147499A (ja) * | 2005-01-27 | 2013-08-01 | Binding Site Group Ltd | 悪性プラズマ細胞疾患を検出又はモニタリングするための抗体及びキット |
JP2013150607A (ja) * | 2006-10-19 | 2013-08-08 | Csl Ltd | インターロイキン−13レセプターアルファ1の高親和性抗体アンタゴニスト |
US9777062B2 (en) | 2006-10-19 | 2017-10-03 | Csl Limited | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
EP2530090A2 (fr) | 2006-10-19 | 2012-12-05 | CSL Limited | Anticorps anti-IL-13R alpha 1 et leurs utilisations |
US7754213B2 (en) | 2006-10-19 | 2010-07-13 | Merck & Co., Inc. | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
JP2010507364A (ja) * | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | インターロイキン−13レセプターアルファ1の高親和性抗体アンタゴニスト |
US8568722B2 (en) | 2006-10-19 | 2013-10-29 | Csl Limited | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
US8613925B2 (en) | 2006-10-19 | 2013-12-24 | Csl Limited | Anti-IL-13Rα1 antibodies and their uses thereof |
EP2829551A1 (fr) | 2006-10-19 | 2015-01-28 | CSL Limited | Anticorps antagonistes de haute affinité dirigés contre le récepteur alpha 1 de interleukin-13 |
US9371388B2 (en) | 2006-10-19 | 2016-06-21 | Csl Limited | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
US8207304B2 (en) | 2006-10-19 | 2012-06-26 | Csl Limited | Antibody antagonists of interleukin-13 receptor α1 |
US10106617B2 (en) | 2006-10-19 | 2018-10-23 | Csl Limited | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
WO2020197502A1 (fr) | 2019-03-26 | 2020-10-01 | Aslan Pharmaceuticals Pte Ltd | Traitement faisant intervenir un anticorps anti-il-13r ou un fragment de liaison de celui-ci |
WO2022186773A1 (fr) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DE LA DERMATITE ATOPIQUE À L'AIDE D'UN ANTICORPS ANTI-IL-13Rα1 OU D'UN FRAGMENT DE LIAISON ASSOCIÉ CHEZ UNE POPULATION ALLERGIQUE |
WO2022186772A1 (fr) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DE LA DERMATITE ATOPIQUE À L'AIDE D'UN ANTICORPS ANTI-IL-13Rα1 OU D'UN FRAGMENT DE LIAISON ASSOCIÉ |
WO2023048651A1 (fr) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Procédé de traitement de la dermatite atoptique modérée à grave |
WO2023048650A1 (fr) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DU PRURIT FAISANT INTERVENIR UN ANTICORPS ANTI-IL13Rα1 OU UN FRAGMENT DE LIAISON DE CELUI-CI |
WO2023075702A1 (fr) | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Formulation d'anticorps anti-il-13r |
WO2024043837A1 (fr) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | Formulation d'anticorps anti-il13r à haute concentration |
WO2024054157A1 (fr) | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Traitement de la perte de sommeil ou des troubles du sommeil chez des patients atteints de dermatite |
Also Published As
Publication number | Publication date |
---|---|
CA2468950A1 (fr) | 2003-06-05 |
EP1449851A4 (fr) | 2005-11-16 |
JPWO2003046009A1 (ja) | 2005-04-07 |
EP1449851A1 (fr) | 2004-08-25 |
AU2002361122A1 (en) | 2003-06-10 |
US20050154192A1 (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003046009A1 (fr) | Anticorps de neutralisation du recepteur alpha 1 de l'il13 | |
WO2003012119A3 (fr) | Procede d'amplification de l'acide nucleique | |
EP0652436A3 (fr) | Biodétecteur pour la mesure de la concentration d'alcool, méthode pour la fabrication du biodétecteur, et appareil pour la détermination du degré de l'ivresse utilisant ce biodétecteur. | |
WO2002077604A3 (fr) | Cellules marquees servant de temoin fonctionnel interne dans des essais de detection de cellules rares | |
AU5782900A (en) | Secure, limited-access database system and method | |
WO2000001845A3 (fr) | Methode de diagnostic precoce de carcinomes | |
AU2023199A (en) | Methods, systems, and kits for intravascular nucleic acid delivery | |
WO2004050839A3 (fr) | Procedes et systemes de detection et d'analyse de variations de sequences bases sur la fragmentation | |
AU2002365812A1 (en) | Parallel computing system, method and architecture | |
WO2004034232A3 (fr) | Procede et systeme permettant de choisir entre plusieurs alternatives | |
WO2005050224A3 (fr) | Agencements de peptides et de petites molecules et leurs utilisations | |
AU2001251063A1 (en) | 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | |
AU2003241431A1 (en) | Fluid-handling system, components and method | |
WO2003020932A1 (fr) | Nouvelles proteines de secretion et adn associe | |
AU2003268546A1 (en) | Lentiviral vectors, related reagents, and methods of use thereof | |
AU2002359776A1 (en) | Conductimetric biosensor device, method and system | |
WO1999020747A3 (fr) | NOUVELLE KINASE HUMAINE POINT DE CONTROLE, hCDS1, COMPOSITIONS ET METHODES ASSOCIEES | |
WO2002054072A3 (fr) | Essai biologique permettant d'evaluer l'efficacite du traitement d'une infection mycobacterienne | |
AU5906699A (en) | (neisseria spp.) polypeptide, nucleic acid sequence and uses thereof | |
CA2361987A1 (fr) | Proteine de liaison a l'antigene du syndrome de goodpasture | |
AU2003226131A1 (en) | Novel human cell surface protein with immunoglobulin folds, bgs-19 | |
WO2005051985A3 (fr) | Procedes de purification de l'anatoxine coquelucheuse et peptides utiles pour ceux-ci | |
WO2004096156A3 (fr) | Effecteur du recepteur tlr 9 et ses utilisations | |
AU2003244237A1 (en) | Monoclonal antibody against adiponectin, preparation method and use thereof | |
WO2001019973A3 (fr) | Recepteur nicotinique de l'acetylcholine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003547458 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10496869 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002795425 Country of ref document: EP Ref document number: 2468950 Country of ref document: CA Ref document number: 2002361122 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002795425 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002795425 Country of ref document: EP |